Thyme Care will use the Series E financing to accelerate growth and establish Thyme Companies for additional oncology businesses.
- Amount
- $125M
- Stage
- Series E
- Announced
- 2 September 2026
- Lead
- Morgan Health
- Other investors
- Humana, CVS Health Ventures, AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures, a16z Bio + Health
- Use of funds
- Accelerate Thyme Care's growth and establish Thyme Companies, a parent entity building a broader portfolio of oncology businesses.
- Valuation
- $2B
- Checked
- Announced by the company